BioWorld-International-2007-07-11
Silence Signs AstraZeneca To $400M Respiratory Drug Deal
Silence Signs AstraZeneca To $400M Respiratory Drug Deal
In its largest deal to date, RNAi firm Silence Therapeutics plc is partnering with AstraZeneca plc in a potential £200 million (US$400 million) to develop drugs against respiratory disease targets. (BioWorld International)

